Andrada Mining acquisition elevates the miner to emerging mid-tier status. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Regulatory News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,328.00
Bid: 12,346.00
Ask: 12,348.00
Change: -228.00 (-1.82%)
Spread: 2.00 (0.016%)
Open: 12,512.00
High: 12,554.00
Low: 12,328.00
Prev. Close: 12,556.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Total Voting Rights

3 Aug 2015 15:00

RNS Number : 9096U
AstraZeneca PLC
03 August 2015
 



Transparency Directive

Voting Rights and Capital

 

The following notification is made in accordance with the UK Financial Conduct Authority's Disclosure and Transparency Rule 5.6.1. On 31 July 2015 the issued share capital of AstraZeneca PLC with voting rights is 1,263,665,297 ordinary shares of US$0.25. No shares are held in Treasury. Therefore, the total number of voting rights in AstraZeneca PLC is 1,263,665,297.

 

The above figure for the total number of voting rights may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, AstraZeneca PLC under the UK Financial Conduct Authority's Disclosure and Transparency Rules.

 

 

A C N Kemp

Company Secretary

3 August 2015

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TVRLLFFVTFIVIIE
Date   Source Headline
8th May 20187:00 amRNSAZ and Luye Pharma enter agreement for Seroquel
4th May 201812:00 pmRNSDirector Declaration
1st May 20183:00 pmRNSTotal Voting Rights
27th Apr 201812:30 pmRNSAZ: positive CHMP for Tagrisso first-line nsclc
24th Apr 20187:00 amRNSAstraZeneca:high level results of the ARCTIC trial
24th Apr 20187:00 amRNSIssue of Equity - AstraZeneca
19th Apr 20187:00 amRNSFDA approves Tagrisso for 1st-line use in NSCLC
13th Apr 201811:00 amRNSNotice of AGM
5th Apr 20187:00 amRNSDirectorate Change
3rd Apr 20183:00 pmRNSTotal Voting Rights
3rd Apr 20187:00 amRNSFDA TO REVIEW MOXETUMOMAB FOR HAIRY CELL LEUKAEMIA
3rd Apr 20187:00 amRNSAZ AND MSD SUBMIT LYNPARZA FOR BREAST CANCER IN EU
28th Mar 20183:00 pmRNSDirector/PDMR Shareholding
26th Mar 20183:00 pmRNSDirector/PDMR Shareholding
22nd Mar 20184:48 pmRNSLokelma approved in the EU
12th Mar 20187:00 amRNSASTRAZENECA UPDATES MYSTIC TRIAL TIMELINE
7th Mar 20187:00 amRNSFiling of Form 20-F with SEC
6th Mar 201811:00 amRNSAnnual Financial Report
1st Mar 20183:00 pmRNSTotal Voting Rights
23rd Feb 201812:35 pmRNSLynparza CHMP for ovarian cancer maintainance
19th Feb 20187:00 amRNSAstraZeneca's IMFINZI approved for Stage III nsclc
15th Feb 20187:00 amRNSSelumetinib in NF1 gets FDA orphan drug status
5th Feb 20182:00 pmRNSDirector/PDMR Shareholding
2nd Feb 20187:00 amRNSAZN: Full-Year 2017 Results
1st Feb 20183:00 pmRNSTotal Voting Rights
26th Jan 20186:20 pmRNSAZ Reports Phase III Results for PT010 in COPD
26th Jan 20187:00 amRNSAZ Reports Phase III Results for PT010 in COPD
19th Jan 20187:00 amRNSASTRAZENECA'S FASENRA RECEIVES APPROVAL IN JAPAN
19th Jan 20187:00 amRNSLYNPARZA APPROVED IN JAPAN FOR OVARIAN CANCER
12th Jan 20184:10 pmRNSFDA approves Lynparza for metastatic breast cancer
10th Jan 20183:10 pmRNSAstraZeneca's Fasenra approved in the EU
2nd Jan 20183:00 pmRNSTotal Voting Rights
28th Dec 20172:00 pmRNSDirector/PDMR Shareholding
18th Dec 20177:00 amRNSFDA accepts Tagrisso submission for 1st-line nsclc
15th Dec 201712:00 pmRNSDirector/PDMR Shareholding
1st Dec 20173:00 pmRNSBlock listing Interim Review
1st Dec 20173:00 pmRNSTotal Voting Rights
28th Nov 20177:00 amRNSEMA accepts Tagrisso submission for 1st-line nsclc
27th Nov 20177:00 amRNSAZ submits Tagrisso in Japan for 1st-line nsclc
15th Nov 20177:00 amRNSAZ Fasenra receives FDA approval for severe asthma
10th Nov 201711:35 amRNSBENRALIZUMAB POSITIVE CHMP IN EOSINOPHILIC ASTHMA
9th Nov 20177:00 amRNSAZN: Year-To-Date and Q3 2017 Results Announcement
1st Nov 20173:00 pmRNSTotal Voting Rights
1st Nov 20177:03 amRNSASTRAZENECA AND ASPEN COMPLETE ANAESTHETICS DEAL
1st Nov 20177:00 amRNSAstraZeneca tralokinumab update in severe asthma
31st Oct 20175:05 pmRNSUS FDA approves AstraZeneca's Calquence for MCL
23rd Oct 20177:05 amRNSAZ and MSD rapidly advance Lynparza in Japan
23rd Oct 20177:00 amRNSUS FDA approves Bydureon BCise for type-2 diabetes
18th Oct 20177:00 amRNSFDA Priority Review for Lynparza in breast cancer
17th Oct 20177:00 amRNSFDA accepts sBLA file for Imfinzi; priority review

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.